Furthermore, KEYNOTE-048 results showed that Pembrolizumab improved OS in patients with R/M HNSCC as PD-L1 increases, demonstrating the role of the PD-L1 expression is a demonstrator of response for ICIs [44]. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.